Akari Therapeutics, Plc
AKTX
$1.12
-$0.03-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.02% | 78.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.93% | 131.91% | |||
| Operating Income | 17.93% | -131.91% | |||
| Income Before Tax | 1.78% | -30.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.78% | -30.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.78% | -30.29% | |||
| EBIT | 17.93% | -131.91% | |||
| EBITDA | 17.99% | -131.86% | |||
| EPS Basic | 30.20% | 18.11% | |||
| Normalized Basic EPS | 4.12% | 3.75% | |||
| EPS Diluted | 30.20% | 18.11% | |||
| Normalized Diluted EPS | 4.12% | 3.75% | |||
| Average Basic Shares Outstanding | 40.63% | 59.17% | |||
| Average Diluted Shares Outstanding | 40.21% | 61.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||